Clinical trials for Diffuse large B-cell lymphoma with chronic inflammation
35 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- ACTIVE NOT RECRUITINGPhase 2NCT07538180Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCLSun Yat-sen University
- RECRUITINGNCT07070648Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PETFudan University · PI: Rong Tao, M.D
- RECRUITINGPHASE1, PHASE2NCT06829771Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell LymphomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPhase 3NCT06717347A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)Merck Sharp & Dohme LLC · PI: Medical Director
- RECRUITINGPhase 2NCT06687772CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell TransplantWashington University School of Medicine · PI: Amanda F Cashen, M.D.
- RECRUITINGPHASE1, PHASE2NCT06760039Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCLSun Yat-sen University
- RECRUITINGPhase 2NCT06701357CR-CHOP+X in Previously Untreated DELRuijin Hospital
- RECRUITINGPhase 2NCT06664411Pola-ZR2P in Previously Untreated DLBCLNavy General Hospital, Beijing · PI: Liren Qian, PhD
- RECRUITINGPhase 2NCT06554600A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGNCT06755775PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell LymphomaRuijin Hospital
- RECRUITINGN/ANCT06352242Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?University Hospital, Montpellier · PI: Ludovic GABELLIER, MD
- RECRUITINGNCT06161896Characterization and Clinical Impact of the Gut Microbiota in LymphomaLars Møller Pedersen · PI: Christiane Sophie Staxen, MSc
- RECRUITINGNCT06774326Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With AnthracyclinesIRCCS Azienda Ospedaliero-Universitaria di Bologna · PI: Vincenzo Russo, MD
- RECRUITINGNCT06694779Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) StudyFondazione IRCCS San Gerardo dei Tintori
- ACTIVE NOT RECRUITINGPhase 2NCT05660967Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell LymphomaGenmab
- RECRUITINGPHASE1, PHASE2NCT05256641Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell LymphomaJonsson Comprehensive Cancer Center · PI: Caspian Oliai, MD
- RECRUITINGN/ANCT05809180Pro-miniCHOP-like Regimen for Treatment-naive Elderly PatientsThe First Affiliated Hospital of Soochow University
- ACTIVE NOT RECRUITINGPhase 2NCT05253118Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)Seoul National University Hospital · PI: Tae Min Kim, PhD., M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT05451810A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular LymphomaGenmab · PI: ABBVIE INC.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05222555Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL PatientsIncyte Corporation · PI: Incyte Medical Director
- ACTIVE NOT RECRUITINGPhase 2NCT05221645Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell LymphomaUniversity of Southampton
- ACTIVE NOT RECRUITINGPhase 2NCT04594798A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCLUniversity of Rochester · PI: Patrick Reagan
- RECRUITINGN/ANCT05040555R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burdenoubai, MD/PhD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04914741A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)Peter MacCallum Cancer Centre, Australia · PI: Michael Dickinson
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT04799275Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell LymphomaNational Cancer Institute (NCI) · PI: Elizabeth A Brem
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04661007To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)Incyte Biosciences Japan GK
- ACTIVE NOT RECRUITINGPhase 2NCT04479267Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated LymphomaBarbara Ann Karmanos Cancer Institute · PI: Dipenkumar Modi, M.D.
- RECRUITINGPhase 3NCT04332822A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell LymphomaNordic Lymphoma Group · PI: Mats Jerkeman
- ACTIVE NOT RECRUITINGPhase 3NCT03274492A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell LymphomaHoffmann-La Roche · PI: Clinical Trials
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03064867Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell LymphomaMolly Gallogly · PI: Molly Gallogly, MD PhD
- ACTIVE NOT RECRUITINGPhase 2NCT02734771A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)Patrick Reagan · PI: Patrick M Reagan, MD
- ACTIVE NOT RECRUITINGPhase 2NCT02227251Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Karyopharm Therapeutics Inc
- ACTIVE NOT RECRUITINGPhase 1NCT02051257Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin LymphomaCity of Hope Medical Center · PI: Elizabeth Budde, MD, PhD
- ACTIVE NOT RECRUITINGPhase 2NCT01856192Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell LymphomaNational Cancer Institute (NCI) · PI: Grzegorz S Nowakowski
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT00972478Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaNational Cancer Institute (NCI) · PI: Daniel O Persky